Lilly – Investorempires.com

Roche falls while Novo, Lilly gain on weight-loss drug report (OTCQX:RHHBY)

Hims & Hers Health declines as Lilly launches single-dose vials of Zepbound By Investing.com

ResMed stock a buy despite Lilly impact: Barron’s (NYSE:RMD)

Eli Lilly to buy bowel disease drug developer Morphic for $3.2 billion By Reuters

UK Planning Laws Hinder Investment, Warns Eli Lilly CEO

Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2

SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY)

Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

Denmark’s Novo Nordisk expects 27% sales surge this year but faces price pressure for weight loss drug Wegovy amid Eli Lilly competition

Jefferies sets Eli Lilly price target to $814 By Investing.com